SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.19-1.4%Dec 30 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (22472)1/11/2007 2:34:57 PM
From: keokalani'nui  Read Replies (2) of 52153
 
Supremely bad reporting.

"Ms. McDaniels, 48, the Mississippi bakery worker, uses two of the newer insulins, NovoLog by Novo Nordisk and Lantus by Sanofi-Aventis. And the $115 a month she spends is about the average monthly cost of insulin treatment in this country."

That's the rub! The analogues and new formulations--even novolin--are substantial improvements over bovine or even rH insulin. Lantus, levemir and novolin are the product of considerable effort. They have patent protection, so why is the reporter suggesting the barrier to generics is the FDA? I don't believe any of the analogues are off patent yet.

"If generic guidelines are set, there will be companies interested in entering the United States market, according to Kathleen D. Jaeger, president of the Generic Pharmaceutical Association."



The place to achieve savings in diabetes is BG monitoring. If you do it right you can be sticking 6-8 times a day. $1/test strip.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News